Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer: study protocol for a phase II diagnostic imaging trial

Renske Altena, Thuy A. Tran, Una Kjällquist, Mattias Karlsson, Jonathan Siikanen, Emma Jussing, Antonios Tzortzakakis, Olof Jonmarker, Rimma Axelsson, Jonas Bergh
doi: https://doi.org/10.1101/2023.03.13.23287203

Article usage

Article usage: March 2023 to November 2024

AbstractFullPdf
Mar 2023421733
Apr 202355114
May 20233015
Jun 20234057
Jul 20231612
Aug 202326127
Sep 20232347
Oct 20231857
Nov 20232064
Dec 20231203
Jan 20241006
Feb 20241814
Mar 2024513
Apr 2024701
May 20241304
Jun 2024935
Jul 20249113
Aug 20241854
Sep 20242138
Oct 2024927
Nov 202422115
Back to top
Posted March 14, 2023.
Download PDF
Data/Code
Email
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer: study protocol for a phase II diagnostic imaging trial
Renske Altena, Thuy A. Tran, Una Kjällquist, Mattias Karlsson, Jonathan Siikanen, Emma Jussing, Antonios Tzortzakakis, Olof Jonmarker, Rimma Axelsson, Jonas Bergh
medRxiv 2023.03.13.23287203; doi: https://doi.org/10.1101/2023.03.13.23287203
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area